Behind the Scenes of Amgen's Latest Options Trends
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
pharmaphorum23h
Amgen's Soliris biosimilar clears phase 3, but won't launch until 2025
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...
24/7 Wall St. on MSN9h
2025’s Five Highest Yielding Dogs of the Dow Could Explode Higher
The ‘Dogs of the Dow’ is a well-known strategy first published in 1991 by Michael Higgins. The plan seeks to maximize the ...